Byrd John C, Lin Thomas S, Grever Michael R
Division of Hematology and Oncology, The Ohio State University, The Arthur James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Semin Oncol. 2006 Apr;33(2):210-9. doi: 10.1053/j.seminoncol.2006.01.012.
There are several initial therapies available for chronic lymphocytic leukemia (CLL) that offer extended disease-free or treatment-free survival time. However, once patients relapse, particularly after fludarabine-based therapy, treatment choices have remained limited. Newer therapies have now become available, including alemtuzumab, fludarabine-based combinations, rituximab, methylprednisolone, alternative nucleoside analogs, flavopirodol, lenalidomide, signal transduction inhibitors/small molecules, and new monoclonal antibodies. We discuss selection of therapy for the relapsed patient using risk stratification and the role of clinical research in continuing to pursue therapeutic advances against CLL.
有几种针对慢性淋巴细胞白血病（CLL）的初始疗法，可延长无病生存期或无需治疗的生存时间。然而，一旦患者复发，尤其是在接受基于氟达拉滨的治疗后，治疗选择仍然有限。现在已有更新的疗法，包括阿仑单抗、基于氟达拉滨的联合疗法、利妥昔单抗、甲泼尼龙、替代核苷类似物、黄酮哌醇、来那度胺、信号转导抑制剂/小分子以及新型单克隆抗体。我们将讨论如何根据风险分层为复发患者选择治疗方法，以及临床研究在持续推进针对CLL的治疗进展中所起的作用。
